Compare Regeneron Pharmaceuticals Inc (REGN) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs TORM plc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while TORM plc trades at $29.52 (market cap $3.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 23.1× TORM plc's market cap, and TORM plc pays the higher dividend (9.37%). Which is the better fit depends on your goals.
| REGN | TRMD | |
|---|---|---|
Market Cap | $70.79B | $3.06B |
Sector | Health | Technology |
52-Week High | $812.27 | $34.87 |
52-Week Low | $545.46 | $18.07 |
Enterprise Value | $64.74B | $3.95B |
Dividend Yield | 0.56% | 9.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
TRMD trades at $29.08, up 2.21% today, with a bullish technical signal from moving averages. The company reported strong 2025 results with $1.34B revenue and $285.3M net income, though recent Q1 2026 EPS missed expectations. Valuation ratios appear attractive with a P/E of 8.54 and P/S of 2.08. Recent news highlights strong cash generation and a potential merger with Hafnia.
The outlook is positive with 100% analyst buy ratings and a near 9% dividend yield. Key risks include earnings volatility and market exposure, but disciplined capital allocation and high profitability margins support upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
